Wednesday, July 8, 2026

Drug profile · INN

pemetrexed sodium

pemetrexed sodium (PEMETREXED) is a thymidylate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 4
Pipeline programs 116
News articles 0
Drug details — pemetrexed sodium
US status
approved
Class
Route
INJECTION
Patents
4
Programs
116
Data quality
0.89

Quick answer

pemetrexed sodium (PEMETREXED) is a thymidylate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN pemetrexed sodium
Brand PEMETREXED
Mechanism Thymidylate synthase inhibitor
Target Dihydrofolate reductase
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Thymidylate synthase inhibitor

Primary target: Dihydrofolate reductase

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 22615 Phase 3 · Bayer · Advanced non-small cell lung cancer with HER2 (ERBB2) mutati
  2. 61186372NSC3001 Phase 3 · Janssen-Cilag International N.V · EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-S
  3. 61186372NSC3002 Phase 3 · Janssen-Cilag International N.V · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  4. APHP241011 Phase 3 · PARItec · Adult patients with stage IV non squamous non-small cell lun
  5. Abraxane /ml powder for dispersion for infusion. for metastatic NSCLC patients Phase 3 · Telethon Foundation · metastatic NSCLC patients
  6. BNT327-06 Phase 3 · BioNTech SE · Non-small cell lung cancer
  7. BO42864 Phase 3 · HOFFMANN-LA ROCHE · RET fusion−positive, metastatic Non-Small Cell Lung Cancer
  8. C6461001 Phase 3 · First Biotech (Australia) · LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Related & competitor drugs

  1. aminosalicylate sodium Dihydrofolate reductase inhibitor
  2. methotrexate sodium Dihydrofolate reductase inhibitor
  3. pemetrexed disodium Thymidylate synthase inhibitor
  4. pralatrexate Antineoplastic and immunomodulating agents (L01)
  5. pyrimethamine Dihydrofolate reductase inhibitor
  6. trimethoprim Bacterial dihydrofolate reductase inhibitor
  1. US 11612662

    Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 10736969

    Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. EP 2882753

    VERFAHREN ZUR HERSTELLUNG VON PEMETREXED UND EINEM LYSINSALZ DAVON

    Expires Tue Jun 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 8952153

    One pot process for preparing pemetrexed disodium

    Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is pemetrexed sodium?

pemetrexed sodium (PEMETREXED) is a thymidylate synthase inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for pemetrexed sodium?

PEMETREXED is a marketed brand name for pemetrexed sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of pemetrexed sodium?

pemetrexed sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.